RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA (1) and Revises Upwards 2025 Financial Guidance Ranges Total Company Revenue increased 8.4% to a qua

RadNet Reports Second Quarter Financial Results with Record Quarterly

Revenue and Adjusted EBITDA(1) and Revises Upwards 2025 Financial Guidance Ranges

LOS ANGELES, California, August 11, 2025 -

RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging

services through a network of 405 owned and operated outpatient imaging centers, today reported financial results for its second quarter

Dr. Howard Berger, President and Chief Executive

Officer of RadNet, commented, "Both the Imaging Center and Digital Health reportable operating segments demonstrated strong growth

and achieved record quarterly results. In the second quarter of 2025, total Company Revenue grew 8.4% and Digital Health segment Revenue

increased 30.9% from last year's same quarter. Growth was driven by strong increases in aggregate and same center procedural volumes,

improved reimbursement from commercial and capitated payors, a continuing shift in procedural volumes towards advanced imaging modalities

and incremental Digital Health sales and licenses of workflow software and AI solutions."

Dr. Berger continued, "Our focus has been

on driving more advanced imaging procedures (MRI, CT and PET/CT) and increasing advanced imaging capacity at the imaging centers through

a variety of initiatives. Within MRI, the 9.0% aggregate and 6.6% same center growth in the second quarter as compared with last year's

second quarter is partially the result of capacity created from investments made in MRI software upgrades and operating protocols which

enable shorter scan times. CT programs have expanded on both coasts to offer more complex procedures, such as Cardiac CT Angiography,

which is often enhanced with AI-assisted analytics. Within PET/CT, our fastest growing modality with 22.4% growth from last year's

second quarter, emphasis has been on newer diagnostic and screening offerings for prostate cancer, Alzheimer's disease and dementia

and new procedures with leading-edge tumor-specific radioactive tracers. The growth in advanced imaging, particularly MRI, has been furthered

by the implementation of Digital Health's TechLiveTM, our remote screening technology recently cleared by the FDA. TechLiveTM

is assisting with ongoing technologist staffing challenges by enabling remote control of advanced imaging equipment to expand hours of

operation and by staffing exam rooms which otherwise would have been closed."

"The growth in advanced imaging from these

initiatives along with effective cost management contributed to an increase in our Adjusted EBITDA(1) margin to 16.3% during

the second quarter of 2025, which compares with 15.7% in last year's second quarter, an improvement of 57 basis points. Adjusted

EBITDA(1) during the second quarter of 2025 increased by 12.3% to $81.2 million from $72.3 million in last year's second

quarter," added Dr. Berger.

Dr. Berger continued, "In response to high

demand and patient backlogs in many of RadNet's local markets, we continue to pursue capacity expansion through the development

and construction of new imaging centers. One new facility was opened during the second quarter in East Brunswick, New Jersey, and nine

additional de novo facility openings are projected for the remainder of 2025. Within Digital Health, we continue to see growth from the

nationwide expansion of the AI-powered Enhanced Breast Cancer Detection program, where today almost 45% of RadNet screening mammography

patients are electing to participate for a $40 out-of-pocket charge. We continue to make progress with the internal RadNet implementation

of the TechLiveTM remote scanning solution, elements of the DeepHealth Operations and Diagnostic suites and the newly acquired

See-Mode ultrasound AI capabilities."

"Given the sustainable positive trends we

are experiencing and the strong financial performance of the second quarter, we are revising upwards 2025 guidance levels for Revenue

and Adjusted EBITDA(1) in anticipation of financial results that we believe will exceed both our original expectations and

the amendments we made to the guidance ranges upon releasing first quarter 2025 results in May," concluded Dr. Berger.

Second Quarter Financial Results

For the second quarter

of 2025, RadNet reported Total Company Revenue of $498.2 million and Adjusted EBITDA(1) of $81.2 million. Revenue increased

$38.5 million (or 8.4%) and Adjusted EBITDA(1) increased $8.9 million (or 12.3%) as compared with the second quarter of 2024.

For the second quarter of 2025, RadNet reported

Digital Health Revenue (inclusive of intersegment revenue) of $20.7 million and Adjusted EBITDA(1) of $3.4 million. Revenue

increased $4.9 million (or 30.9%) and Adjusted EBITDA(1) increased $134,000 (or 4.1%) as compared with the second quarter of

Unadjusted for unusual

or one-time items impacting the second quarter of 2025, Total Company Net Income for the second quarter of 2025 was $14.5 million as compared

with a Total Company Net Loss of $3.0 million for the second quarter of 2024. Net Income Per Share for the second quarter of 2025 was

$0.19, compared with a Net Loss per share of $(0.04) in the second quarter of 2024, based upon a weighted average number of diluted shares

outstanding of 75.5 million shares in 2025 and 73.4 million shares in 2024.

of unusual or one-time items impacting the second quarter including: $2.0 million of non-cash loss from interest rate swaps; $496,000

expense related to leases for de novo facilities under construction that have yet to open their operations; $123,000 of lease abandonment

charge; $2.3 million of acquisition transaction costs; and $4.8 million of non-capitalized research and development expenses related to

the DeepHealth Cloud OS and generative AI. Adjusting for the above items, Total Company Adjusted Earnings(3) was $23.8 million

and diluted Adjusted Earnings Per Share(3) was $0.31 during the second quarter of 2025. This compares with Total Company Adjusted

Earnings(3) of $12.0 million and diluted Adjusted Earnings Per Share(3) of $0.16 during the second quarter of 2024.

For the second quarter of 2025, as compared with

the prior year's second quarter, MRI volume increased 9.0%, CT volume increased 8.1%, PET/CT volume increased 22.4% and routine

imaging (inclusive of nuclear medicine, ultrasound, mammography, x-ray and other exams) increased 3.5% over the prior year's second

quarter. On a same-center basis, including only those centers which were part of RadNet for both the second quarters of 2025 and 2024,

MRI volume increased 6.6%, CT volume increased 5.9%, PET/CT volume increased 16.2% and routine imaging increased 1.4% over the prior year's

Six Month Financial Results

For the first six months of 2025, RadNet reported

Total Company Revenue of $969.6 million and Adjusted EBITDA(1) of $127.6 million. Revenue increased $78.2 million (or 8.8%)

and Adjusted EBITDA(1) decreased $3.1 million (or 2.4%) as compared with the first six months of 2024. The decrease in Adjusted

EBITDA(1) was primarily the result of the previously estimated loss of $15 million of Adjusted EBITDA(1) as a result

of the California wildfires and severe winter weather conditions impacting the first quarter of 2025.

For the first six months of 2025, RadNet reported

Digital Health Revenue (inclusive of intersegment revenue) of $39.9 million and Adjusted EBITDA(1) of $7.1 million. Revenue

increased $9.5 million (or 31.0%) and Adjusted EBITDA(1) increased $325,000 (or 4.8%) as compared with the first six months

Unadjusted for one-time or unusual items, Total

Company Net Loss for the first six months of 2025 was $23.5 million as compared with a Total Company Net Loss of $5.8 million for the

first six months of 2024. Net Loss Per Share for the six-month period of 2025 was $(0.32), compared with a Net Loss per share of $(0.08)

in the six-month period of 2024, based upon a weighted average number of diluted shares outstanding of 74.1 million shares in 2025 and

71.8 million shares in 2024.

2025 Guidance Update

RadNet updates guidance levels as follows:

Imaging Center Segment

Digital Health Segment

Conference Call for Tomorrow

Dr. Howard Berger, President and Chief Executive

Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its second quarter

2025 results on Monday, August 11th, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Conference Call Details:

Date: Monday, August 11, 2025

Time: 10:30 a.m. Eastern Time

Dial In-Number: 844-826-3035

International Dial-In Number: 412-317-5195

It is recommended that participants dial in approximately

5 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1729070&tp_key=3a3e8702a3

or http://www.radnet.com under the "Investors" menu section and "News Releases" sub-menu of the website. An archived

replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international

callers, and using the passcode 10201853.

RadNet, Inc. is a leading national provider of

freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.